420 related articles for article (PubMed ID: 26855409)
1. Meningococcal Conjugate and Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccination Among HIV-infected Youth.
Setse RW; Siberry GK; Moss WJ; Wheeling J; Bohannon BA; Dominguez KL;
Pediatr Infect Dis J; 2016 May; 35(5):e152-7. PubMed ID: 26855409
[TBL] [Abstract][Full Text] [Related]
2. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
America Academy of Pediatrics Commitee on Infectious Diseases
Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
[TBL] [Abstract][Full Text] [Related]
3. Effect of Tdap upon antibody response to meningococcal polysaccharide when administered before, with or after the quadrivalent meningococcal TT-conjugate vaccine (coadministered with the 13-valent pneumococcal CRM197-conjugate vaccine) in adult Hajj pilgrims: A randomised controlled trial.
Tashani M; Alfelali M; Barasheed O; Alqahtani AS; Heron L; Wong M; Rashid H; Findlow H; Borrow R; Booy R
Vaccine; 2018 Jul; 36(29):4375-4382. PubMed ID: 29880243
[TBL] [Abstract][Full Text] [Related]
4. A Phase 2, Randomized, Active-controlled, Observer-blinded Study to Assess the Immunogenicity, Tolerability and Safety of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered With Tetanus, Diphtheria and Acellular Pertussis Vaccine and Serogroup A, C, Y and W-135 Meningococcal Conjugate Vaccine in Healthy US Adolescents.
Muse D; Christensen S; Bhuyan P; Absalon J; Eiden JJ; Jones TR; York LJ; Jansen KU; O'Neill RE; Harris SL; Perez JL
Pediatr Infect Dis J; 2016 Jun; 35(6):673-82. PubMed ID: 26974889
[TBL] [Abstract][Full Text] [Related]
5. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
Broder KR; Cortese MM; Iskander JK; Kretsinger K; Slade BA; Brown KH; Mijalski CM; Tiwari T; Weston EJ; Cohn AC; Srivastava PU; Moran JS; Schwartz B; Murphy TV;
MMWR Recomm Rep; 2006 Mar; 55(RR-3):1-34. PubMed ID: 16557217
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: results from a randomized open trial.
Wheeler CM; Harvey BM; Pichichero ME; Simon MW; Combs SP; Blatter MM; Marshall GS; Catteau G; Dobbelaere K; Descamps D; Dubin G; Schuind A
Pediatr Infect Dis J; 2011 Dec; 30(12):e225-34. PubMed ID: 21817954
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and reactogenicity of co-administered tetanus-diphtheria-acellular pertussis (Tdap) and tetravalent meningococcal conjugate (MCV4) vaccines compared to their separate administration.
Weston WM; Friedland LR; Wu X; Howe B
Vaccine; 2011 Jan; 29(5):1017-22. PubMed ID: 21134450
[TBL] [Abstract][Full Text] [Related]
8. Changes in Tdap and MCV4 vaccine coverage following enactment of a statewide requirement of Tdap vaccination for entry into sixth grade.
Kharbanda EO; Stockwell MS; Colgrove J; Natarajan K; Rickert VI
Am J Public Health; 2010 Sep; 100(9):1635-40. PubMed ID: 20634463
[TBL] [Abstract][Full Text] [Related]
9. Effect of Tdap when administered before, with or after the 13-valent pneumococcal conjugate vaccine (coadministered with the quadrivalent meningococcal conjugate vaccine) in adults: A randomised controlled trial.
Tashani M; Alfelali M; Barasheed O; Alqahtani AS; Heron L; Wong M; Rashid H; Booy R
Vaccine; 2016 Nov; 34(48):5929-5937. PubMed ID: 27780630
[TBL] [Abstract][Full Text] [Related]
10. Vaccination coverage among adolescents aged 13-17 years - United States, 2007.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2008 Oct; 57(40):1100-3. PubMed ID: 18846032
[TBL] [Abstract][Full Text] [Related]
11. Waning Tdap Effectiveness in Adolescents.
Klein NP; Bartlett J; Fireman B; Baxter R
Pediatrics; 2016 Mar; 137(3):e20153326. PubMed ID: 26908667
[TBL] [Abstract][Full Text] [Related]
12. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trials.
Weston WM; Friedland LR; Wu X; Howe B
Vaccine; 2012 Feb; 30(9):1721-8. PubMed ID: 22212127
[TBL] [Abstract][Full Text] [Related]
13. Adolescent vaccine co-administration and coverage in New York City: 2007-2013.
Sull M; Eavey J; Papadouka V; Mandell R; Hansen MA; Zucker JR
Pediatrics; 2014 Dec; 134(6):e1576-83. PubMed ID: 25384490
[TBL] [Abstract][Full Text] [Related]
14. A population-level assessment of factors associated with uptake of adolescent-targeted vaccines in Michigan.
Gowda C; Dong S; Potter RC; Dombkowski KJ; Dempsey AF
J Adolesc Health; 2013 Oct; 53(4):498-505. PubMed ID: 24054080
[TBL] [Abstract][Full Text] [Related]
15. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel.
Kretsinger K; Broder KR; Cortese MM; Joyce MP; Ortega-Sanchez I; Lee GM; Tiwari T; Cohn AC; Slade BA; Iskander JK; Mijalski CM; Brown KH; Murphy TV; ; ;
MMWR Recomm Rep; 2006 Dec; 55(RR-17):1-37. PubMed ID: 17167397
[TBL] [Abstract][Full Text] [Related]
16. Tetanus and pertussis vaccination coverage among adults aged ≥ 18 years --- United States, 1999 and 2008.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2010 Oct; 59(40):1302-6. PubMed ID: 20948508
[TBL] [Abstract][Full Text] [Related]
17. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults.
Pichichero ME; Rennels MB; Edwards KM; Blatter MM; Marshall GS; Bologa M; Wang E; Mills E
JAMA; 2005 Jun; 293(24):3003-11. PubMed ID: 15933223
[TBL] [Abstract][Full Text] [Related]
18. Economic impact of implementing decennial tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccination in adults in the United States.
Havers FP; Cho BH; Walker JW; Hariri S
Vaccine; 2020 Jan; 38(2):380-387. PubMed ID: 31676198
[TBL] [Abstract][Full Text] [Related]
19. Missed opportunities for adolescent vaccination, 2006-2011.
Wong CA; Taylor JA; Wright JA; Opel DJ; Katzenellenbogen RA
J Adolesc Health; 2013 Oct; 53(4):492-7. PubMed ID: 23809613
[TBL] [Abstract][Full Text] [Related]
20. Effect on meningococcal serogroup W immunogenicity when Tdap was administered prior, concurrent or subsequent to the quadrivalent (ACWY) meningococcal CRM
Tashani M; Badahdah AM; Alfelali M; Barasheed O; Alqahtani AS; Heron L; Wong M; Louth J; Rashid H; Borrow R; Booy R
Vaccine; 2019 Jun; 37(27):3562-3567. PubMed ID: 31128875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
